These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29133566)

  • 41. Physiologically Based Pharmacokinetic Model for Predicting Omadacycline Pharmacokinetics and Pharmacodynamics in Healthy and Hepatic Impairment Populations.
    Zhang A; Sun Y; Zuo M; Wei H; Chen J; Zhao M; Yang W; Zhu L
    Clin Ther; 2024 Aug; 46(8):629-635. PubMed ID: 39069431
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections.
    Noviello S; Corey GR; Holland TL; Lodise T; O'Riordan W; Wilcox MH; File TM; Dryden M; Balser B; Scaramucci A; Torres A; Huang DB
    J Med Microbiol; 2020 Apr; 69(4):625-630. PubMed ID: 32195649
    [No Abstract]   [Full Text] [Related]  

  • 43. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
    Bhavnani SM; Zhang L; Hammel JP; Rubino CM; Bader JC; Sader HS; Gelone SP; Wicha WW; Ambrose PG
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetic evaluation of marbofloxacin after intravenous administration at different ages in llama crias, and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation.
    Rubio-Langre S; Aguilar-Sola S; Lorenzutti AM; San Andrés MI; De Lucas JJ; Litterio NJ
    J Vet Pharmacol Ther; 2018 Dec; 41(6):861-870. PubMed ID: 30020535
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Zazo H; Martín-Suárez A; Lanao JM
    Int J Antimicrob Agents; 2013 Aug; 42(2):155-60. PubMed ID: 23756322
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Worldwide surveillance of Iclaprim activity: In Vitro susceptibility of gram-positive pathogens collected from patients with skin and skin structure infections from 2013 to 2017.
    Huang DB; Charrier C; Hawser S
    Diagn Microbiol Infect Dis; 2020 May; 97(1):115013. PubMed ID: 32081524
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Iclaprim, a novel diaminopyrimidine for the treatment of resistant gram-positive infections.
    Sincak CA; Schmidt JM
    Ann Pharmacother; 2009 Jun; 43(6):1107-14. PubMed ID: 19435963
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How can we predict bacterial eradication?
    Jacobs MR
    Int J Infect Dis; 2003 Mar; 7 Suppl 1():S13-20. PubMed ID: 12839703
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection.
    Ogawa R; Kobayashi S; Sasaki Y; Makimura M; Echizen H
    Int J Clin Pharmacol Ther; 2013 May; 51(5):357-66. PubMed ID: 23458228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
    Pfaller MA; Rhomberg PR; Sader HS; Mendes RE; Jones RN
    J Chemother; 2010 Oct; 22(5):304-11. PubMed ID: 21123152
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.
    James JK; Palmer SM; Levine DP; Rybak MJ
    Antimicrob Agents Chemother; 1996 Mar; 40(3):696-700. PubMed ID: 8851595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe.
    Huang DB; File TM; Dryden M; Corey GR; Torres A; Wilcox MH
    Diagn Microbiol Infect Dis; 2018 Apr; 90(4):329-334. PubMed ID: 29306582
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of the
    Park JH; Craig W; Marchillo K; Huang DB; Andes DR
    Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378717
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection.
    Knudsen JD; Fuursted K; Raber S; Espersen F; Frimodt-Moller N
    Antimicrob Agents Chemother; 2000 May; 44(5):1247-54. PubMed ID: 10770759
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing.
    Tang Z; Guan J; Li J; Yu Y; Qian M; Cao J; Shuai W; Jiao Z
    Int J Antimicrob Agents; 2021 Mar; 57(3):106300. PubMed ID: 33567334
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
    Prokocimer P; Bien P; Deanda C; Pillar CM; Bartizal K
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4608-13. PubMed ID: 22687509
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.
    Yu W; Ji J; Xiao T; Ying C; Fang J; Shen P; Xiao Y
    Drug Des Devel Ther; 2017; 11():1951-1956. PubMed ID: 28721014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.
    Dong H; Wang X; Dong Y; Lei J; Li H; You H; Wang M; Xing J; Sun J; Zhu H
    Int J Antimicrob Agents; 2011 Oct; 38(4):296-300. PubMed ID: 21741222
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical pharmacokinetic and pharmacodynamic analysis of daptomycin and the necessity of high-dose regimen in Japanese adult patients.
    Urakami T; Hamada Y; Oka Y; Okinaka T; Yamakuchi H; Magarifuchi H; Aoki Y
    J Infect Chemother; 2019 Jun; 25(6):437-443. PubMed ID: 30782427
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacodynamics of teicoplanin against MRSA.
    Ramos-Martín V; Johnson A; McEntee L; Farrington N; Padmore K; Cojutti P; Pea F; Neely MN; Hope WW
    J Antimicrob Chemother; 2017 Dec; 72(12):3382-3389. PubMed ID: 28962026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.